Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17017668 | 0.93 | KMT2A (0.37) | KMT2AMEN1ATMCYP19A1ABCG2 | |
| SCHEMBL17017678 | 0.92 | KMT2A (0.33) | KMT2AMEN1ATMCYP19A1ABCG2 | |
| SCHEMBL17017674 | 0.91 | MEN1 (0.36) | KMT2AMEN1ATMABCG2GAA | |
| SCHEMBL17017681 | 0.90 | MEN1 (0.42) | KMT2AMEN1ATMABCG2GAA | |
| SCHEMBL17017675 | 0.90 | MEN1 (0.41) | KMT2AMEN1ATMABCG2GAA | |
| SCHEMBL17017758 | 0.90 | MEN1 (0.31) | KMT2AMEN1ATM | |
| SCHEMBL17017680 | 0.89 | MEN1 (0.36) | KMT2AMEN1ATMABCG2GAA | |
| SCHEMBL15596425 | 0.89 | MEN1 (0.32) | KMT2AMEN1ATMABCG2GAA | |
| SCHEMBL17017679 | 0.88 | MEN1 (0.39) | KMT2AMEN1ATMABCG2GAA | |
| SCHEMBL17017649 | 0.87 | KDM4E (0.34) | KMT2ACYP19A1CYP17A1CYP11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9905777-B2 | Compound and organic electroluminescence device comprising same | DOOSAN CORPORATION (KR) | 2018-02-27 | — | — | US | disclosed |
| US-9905777-B2 | Compound and organic electroluminescence device comprising same | DOOSAN CORPORATION (KR) | 2018-02-27 | — | — | US | disclosed |
| US-20150236271-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
| US-20150236271-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150236271-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | OR10J3, VDAC1, VDAC2 | KMT2A 1420/4885MEN1 1762/4885ATM 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.